Neurology: Literature
Meyer PT, Frings L, Hellwig S.
Update on SPECT and PET in parkinsonism - part 2: biomarker imaging of cognitive impairment in Lewy-body diseases.
Curr Opin Neurol. 2014 Aug;27(4):398-404.
Meyer PT, Hellwig S.
Update on SPECT and PET in parkinsonism - part 1: imaging for differential diagnosis.
Curr Opin Neurol. 2014 Aug;27(4):390-7.
Booth TC, Nathan M, Waldman AD, Quigley AM, Schapira AH, Buscombe J.
The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 2.
AJNR Am J Neuroradiol. 2014 Jun 12.
Booth TC, Nathan M, Waldman AD, Quigley AM, Schapira AH, Buscombe J.
The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1.
AJNR Am J Neuroradiol. 2014 Jun 5.
Grosset DG, Tatsch K, Oertel WH, Tolosa E, Bajaj N, Kupsch A, O'Brien JT, Seibyl J, Walker Z, Sherwin P, Chen C, Grachev ID.
Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane 123I Injection (DaTscan).
J Nucl Med. 2014 Jun 19;55(8):1281-1287.
Cohen AD, Klunk WE.
Early detection of Alzheimer's disease using PiB and FDG PET.
Neurobiol Dis. 2014 May 10.
Sharifi S, Nederveen AJ, Booij J, van Rootselaar AF.
Neuroimaging essentials in essential tremor: A systematic review.
Neuroimage Clin. 2014 May 9;5:217-31.
Morbelli S, Nobili F.
Cognitive reserve and clinical expression of Alzheimer's disease: evidence and implications for brain PET imaging.
Am J Nucl Med Mol Imaging. 2014 Apr 25;4(3):239-47.
Purz S, Sabri O, Viehweger A, Barthel H, Kluge R, Sorge I, Hirsch FW.
Potential Pediatric Applications of PET/MR.
J Nucl Med. 2014 Apr 24;55(Supplement 2):32S-39S.
Leopoldo M, Contino M, Berardi F, Perrone R, Colabufo NA.
PET radiotracers for imaging P-glycoprotein: the challenge for early diagnosis in AD.
ChemMedChem. 2014 Jan;9(1):38-42.
Byrnes KR, Wilson CM, Brabazon F, von Leden R, Jurgens JS, Oakes TR, Selwyn RG.
FDG-PET imaging in mild traumatic brain injury: a critical review.
Front Neuroenergetics. 2014 Jan 9;5:13.
Vandenberghe R, Adamczuk K, Van Laere K.
The interest of amyloid PET imaging in the diagnosis of Alzheimer's disease.
Curr Opin Neurol. 2013 Dec;26(6):646-55.
Omuro A, DeAngelis LM.
Glioblastoma and other malignant gliomas: a clinical review.
JAMA. 2013 Nov 6;310(17):1842-50.
Jack CR Jr, Barrio JR, Kepe V.
Cerebral amyloid PET imaging in Alzheimer's disease.
Acta Neuropathol. 2013 Nov;126(5):643-57.
Nasrallah I, Dubroff J.
An overview of PET neuroimaging.
Semin Nucl Med. 2013 Nov;43(6):449-61.
Vandenberghe R, Adamczuk K, Dupont P, Laere KV, Chételat G.
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease.
Neuroimage Clin. 2013 Apr 6;2:497-511.
Chételat G, La Joie R, Villain N, Perrotin A, de La Sayette V, Eustache F, Vandenberghe R.
Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease.
Neuroimage Clin. 2013 Mar 5;2:356-65.
Gropman AL.
Neuroimaging in mitochondrial disorders.
Neurotherapeutics. 2013 Apr;10(2):273-85.
Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH.
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.
J Nucl Med. 2013 Mar;54(3):476-90.
Benadiba M, Luurtsema G, Tumas V, Buchpigel CA, Busatto GF.
New perspectives in nuclear neurology for the evaluation of Parkinson's disease.
J Parkinsons Dis. 2013 Jan 1;3(3):301-23.
Omuro AM, Leite CC, Mokhtari K, Delattre JY.
Pitfalls in the diagnosis of brain tumours.
Lancet Neurol. 2006 Nov;5(11):937-48.